HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Valcare, Inc., established in 2012 and headquartered in Irvine, California, specializes in the design and development of medical devices and accessories for minimally invasive treatment of heart valve disease. The company's core technology is a transcatheter platform that functions as a docking station for replacement prostheses and a tool for mitral annulus repair, aiming to improve treatment options and accelerate recovery for patients with mitral and tricuspid regurgitation.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

1000Farmacie operates as a leading pharmacy marketplace in Italy, connecting a network of independent pharmacies to enable faster deliveries. It runs an online medical platform that offers a wide range of pharmaceutical products from authorized pharmacies at reasonable prices, with options for same-day delivery to any location, helping customers save time and money.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

SK Biopharmaceuticals Co., Ltd., founded in 2011 and headquartered in Seongnam, South Korea, focuses on the research, discovery, and development of pharmaceuticals targeting central nervous system disorders. The company is advancing several key products, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome, with various candidates in different stages of clinical trials. Other investigational drugs include Relenopride for rare neurological diseases and compounds targeting attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to establish itself as a leading specialty pharmaceutical company by developing innovative treatments and providing high-quality pharmaceutical manufacturing services.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Founded in 2007, Neurelis is a specialty pharmaceutical company based in Encinitas, California. It focuses on licensing, developing, and commercializing product candidates for epilepsy and the broader central nervous system market. The company differentiates itself by applying novel technologies to enhance therapeutic benefits and improve patient care.

Valcare, Inc., established in 2012 and headquartered in Irvine, California, specializes in the design and development of medical devices and accessories for minimally invasive treatment of heart valve disease. The company's core technology is a transcatheter platform that functions as a docking station for replacement prostheses and a tool for mitral annulus repair, aiming to improve treatment options and accelerate recovery for patients with mitral and tricuspid regurgitation.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

Instil Bio develops and commercializes tumor infiltrating lymphocyte (TIL) therapies for treating various cancers. Founded in 2018, the company harvests patients' T cells from tumors, expands them, and reinfuses them to target cancer cells.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Founded in 2007, Neurelis is a specialty pharmaceutical company based in Encinitas, California. It focuses on licensing, developing, and commercializing product candidates for epilepsy and the broader central nervous system market. The company differentiates itself by applying novel technologies to enhance therapeutic benefits and improve patient care.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing innovative therapies for gastrointestinal and immunological diseases. Headquartered in Dublin, Ireland, with an additional office in Solana Beach, California, the company aims to address unmet clinical needs through its proprietary oral drug delivery technology. This technology enhances the bioavailability of difficult-to-formulate drugs, allowing for effective systemic or localized delivery within the gastrointestinal tract. Sublimity Therapeutics' product portfolio includes treatments for conditions such as ulcerative colitis, Crohn’s disease, graft versus host disease, and transplant rejection, as well as SmPill formulations for various gastrointestinal disorders. The company's lead product is STI-0529, specifically designed for moderate to severe ulcerative colitis. Founded in 2000 and formerly known as Sigmoid Pharma, Sublimity Therapeutics is committed to advancing oral pharmaceutical formulation technologies to improve patient outcomes in its targeted therapeutic areas.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Everest Medicines is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for critical unmet medical needs, initially focusing on Asia Pacific markets.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Farmalisto operates an online pharmacy platform that enables customers in Colombia and Mexico to purchase medicines and health-related products through an integrated e-commerce experience. The platform emphasizes chronic and complex medications, offering home delivery, patient support programs, home care services, and laboratory services to support treatment at home or in an office. The business also provides logistics and marketing services to pharmaceutical partners and includes a retail assortment of personal care and health products. Founded in 2013, Farmalisto is based in Bogotá and serves the Latin American market.

Harmony Biosciences Holdings is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. It develops and commercializes therapies for rare neurological disorders with unmet medical needs. Its lead product is WAKIX (pitolisant), used to treat narcolepsy, and the company maintains a pipeline that includes candidates such as HBS-102, BP1.15205, ZYN002, EPX-100 and EPX-200.

MicroOptx, Inc. is a medical device company based in Maple Grove, Minnesota, specializing in innovative solutions for glaucoma treatment. Founded in 2014, the company develops advanced medical devices including the Beacon Aqueous Microshunt (BAM), designed to shunt aqueous humor from the anterior chamber to the surface of the eye, thereby reducing intraocular pressure. Additionally, MicroOptx produces SalVO, a minimally invasive glaucoma surgery micro implant intended for use in animals. The company combines expertise in bioengineering, surgical techniques, microengineering, and nanotechnology to address the challenges posed by glaucoma, a progressive disease that can lead to blindness. With a commitment to improving patient outcomes, MicroOptx aims to revolutionize the treatment landscape for glaucoma.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, which is expressed on various immune system B cells. This candidate is being developed for multiple indications, including neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. Additionally, Viela Bio is advancing VIB4920, aimed at preventing kidney transplant rejection and treating sjögren’s syndrome, as well as VIB7734, which targets cutaneous lupus erythematosus. The company has established a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several Asian markets. Founded in 2017, Viela Bio aims to address critical pathways underlying these diseases and improve patient outcomes globally.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

4TEEN4 Pharmaceuticals develops precision medicines for acute cardiovascular conditions, focusing on restoring cardiac and vascular function in critical care by creating humanized antibodies and related biomarkers and diagnostic tools. Its lead program, Procizumab, is a humanized antibody targeting DPP3 for the treatment of acute cardiovascular diseases. It also develops DPP3 as a diagnostic biomarker for indications such as acute heart failure, myocardial infarction, cardiogenic shock, and septic shock, along with accompanying diagnostic tools. The company evolved from Sphingotec Therapeutics and is based in Hennigsdorf, Germany.

Sublimity Therapeutics is a specialty pharmaceutical company focused on developing innovative therapies for gastrointestinal and immunological diseases. Headquartered in Dublin, Ireland, with an additional office in Solana Beach, California, the company aims to address unmet clinical needs through its proprietary oral drug delivery technology. This technology enhances the bioavailability of difficult-to-formulate drugs, allowing for effective systemic or localized delivery within the gastrointestinal tract. Sublimity Therapeutics' product portfolio includes treatments for conditions such as ulcerative colitis, Crohn’s disease, graft versus host disease, and transplant rejection, as well as SmPill formulations for various gastrointestinal disorders. The company's lead product is STI-0529, specifically designed for moderate to severe ulcerative colitis. Founded in 2000 and formerly known as Sigmoid Pharma, Sublimity Therapeutics is committed to advancing oral pharmaceutical formulation technologies to improve patient outcomes in its targeted therapeutic areas.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for cancer treatment in the United States. The company's lead product, DANYELZA, is an FDA-approved monoclonal antibody targeting ganglioside GD2, which is present in various neuroectoderm-derived tumors and sarcomas. Y-mAbs is advancing several other candidates, including naxitamab, currently in Phase 2 trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, and omburtamab, also in Phase 2 trials for desmoplastic small round cell tumors. Additionally, the company is developing a GD2-GD3 vaccine and exploring the huB7-H3 candidate for adult solid tumors. Y-mAbs collaborates with leading institutions, including Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, to enhance its antibody constructs using advanced therapeutic platforms. Founded in 2015 and headquartered in New York, Y-mAbs aims to provide novel treatments that may reduce the long-term toxicities associated with traditional chemotherapies while potentially offering curative options for patients with widespread disease.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative antibody-based therapies for cancer treatment in the United States. The company's lead product, DANYELZA, is an FDA-approved monoclonal antibody targeting ganglioside GD2, which is present in various neuroectoderm-derived tumors and sarcomas. Y-mAbs is advancing several other candidates, including naxitamab, currently in Phase 2 trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, and omburtamab, also in Phase 2 trials for desmoplastic small round cell tumors. Additionally, the company is developing a GD2-GD3 vaccine and exploring the huB7-H3 candidate for adult solid tumors. Y-mAbs collaborates with leading institutions, including Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, to enhance its antibody constructs using advanced therapeutic platforms. Founded in 2015 and headquartered in New York, Y-mAbs aims to provide novel treatments that may reduce the long-term toxicities associated with traditional chemotherapies while potentially offering curative options for patients with widespread disease.

Harmony Biosciences Holdings is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. It develops and commercializes therapies for rare neurological disorders with unmet medical needs. Its lead product is WAKIX (pitolisant), used to treat narcolepsy, and the company maintains a pipeline that includes candidates such as HBS-102, BP1.15205, ZYN002, EPX-100 and EPX-200.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Amphora Medical, Inc. is a Minnesota-based company that develops innovative medical devices aimed at treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is focused on creating a novel cystoscopic device that utilizes minimally invasive procedures to enhance bladder function. Amphora Medical's technology is designed to improve the quality of life for individuals suffering from OAB, offering a promising solution in the field of urology.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Amicus SA is a pharmaceutical company based in Baar, Switzerland, established in 2013. It specializes in representing research-based pharmaceutical and healthcare companies in the Balkans and the Baltics, particularly in regions where the original companies do not maintain a direct presence. The company offers a range of services, including marketing and sales, regulatory affairs, reimbursement and market access, and logistics management. Amicus also collaborates with local partners for manufacturing and packaging, and provides risk management services encompassing pharmacovigilance, compliance, and quality assurance. Its team is composed of skilled managers and medical professionals committed to delivering modern medicines to these markets while upholding ethical standards in its operations.

Founded in 2007, Neurelis is a specialty pharmaceutical company based in Encinitas, California. It focuses on licensing, developing, and commercializing product candidates for epilepsy and the broader central nervous system market. The company differentiates itself by applying novel technologies to enhance therapeutic benefits and improve patient care.

Vitaeris Inc. is a biopharmaceutical company based in Vancouver, Canada, specializing in the development of innovative treatments for chronic inflammatory diseases. Founded in 2016, Vitaeris focuses on the anti-interleukin-6 monoclonal antibody clazakizumab, which has been licensed from Alder Biopharmaceuticals. The company aims to provide new treatment options that enhance recovery for organ transplant recipients and others suffering from chronic conditions. As of June 2020, Vitaeris operates as a subsidiary of CSL Limited.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

PTC Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for rare genetic disorders. Its portfolio includes approved drugs like Translarna (ataluren) and Emflaza (deflazacort), as well as pipeline candidates targeting various rare diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain cancers.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Vivoryon Therapeutics is a biopharmaceutical company focused on developing therapeutic products for the treatment of Alzheimer's disease and cancer. Its lead product candidate, PQ912, has completed Phase IIb clinical trials for Alzheimer's disease. The company also has preclinical development products targeting cancer and is exploring monoclonal antibody therapies.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.